Leukemia News and Features
Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia
About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.
A subset of antiviral immune cells could prevent CMV infections in bone marrow transplant recipients
A small subset of antiviral immune cells may be enough to fight and even prevent the disease caused by cytomegalovirus (CMV) in patients that receive bone marrow transplants.
Young adult survivors of leukemia and lymphoma are more likely to report high stress compared with older survivors of the same diseases.
The ASCO has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.
A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.
Leukemia Clinical Trials
- New treatment method shrinks ovarian cancer tumors and improves chemotherapy effectiveness
- Epigenetic signatures differentiate triple negative breast cancers
- Women educated on overdiagnsosis are less likely to want mammogram
- Novel drug approved for multiple myeloma
- Radiation therapy used most often for prostate cancer regardless of decision-making factors
- Farydak (panobinostat) now FDA-approved for multiple myeloma
- ASCO: Testicular cancer history may indicate greater risk of developing prostate cancer
- Urine test could help to guide treatment of bladder cancer
- Multiple studies are exploring whether e-cigarettes help smokers quit or continue smoking
- Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|